Explore 3 Stock Ideas & Industry Insights Download Free Report

blue-chip

GMAB: Royalties and Oncology Portfolio Advance as Acquisition Costs Weigh on Earnings

Nov 16, 2026 | Team Kalkine
GMAB: Royalties and Oncology Portfolio Advance as Acquisition Costs Weigh on Earnings
Image source: shutterstock

  • GMAB:NASDAQ
  • Investment Type
    Large-cap
  • Risk Level
  • Action
  • Rec. Price (US$)

Genmab A/S

Genmab A/S (NASDAQ: GMAB) is a Denmark-based biotechnology company that develops antibody therapies, primarily for cancer. Its approved portfolio includes DARZALEX and DARZALEX FASPRO for multiple myeloma, Arzerra for chronic lymphocytic leukemia, Kesimpta for relapsing forms of multiple sclerosis, and TEPEZZA for thyroid eye disease. Genmab uses four proprietary antibody platforms, DuoBody, HexaBody, DuoHexaBody and HexElect, to develop its clinical and preclinical pipeline.

Key Growth Prospects


Disclaimer-

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.

Past performance is not a reliable indicator of future performance.

Support

Hi! How can we help you today?

Loading…